OTC · Healthcare
INTERPACE BIOSCIENCES, INC. (IDXG)
As-reported financials and recent SEC filings for INTERPACE BIOSCIENCES, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$38.7M
Net income
$24.6M
Net margin
63.5%
Diluted EPS
$0.89
ROE
109.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $38.7M | $46.9M | $40.0M | $31.8M | $33.1M |
| Gross profit | $24.1M | $29.9M | $25.1M | $18.2M | $18.8M |
| Operating income | $4.1M | $8.1M | $4.0M | $-3.6M | $-6.3M |
| Net income | $24.6M | $6.7M | $2.0M | $-22.0M | $-14.9M |
| Diluted EPS | $0.89 | $0.40 | $0.11 | $-1.29 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
PREM14A2026-06-25
View on EDGAR →PRE 14A2026-06-23
View on EDGAR →8-K2026-05-14
View on EDGAR →10-Q2026-05-12
View on EDGAR →10-K/A2026-04-30
View on EDGAR →8-K2026-04-01
View on EDGAR →10-K2026-03-30
View on EDGAR →42026-02-17
View on EDGAR →Largest Healthcare peers
Go deeper on IDXG
Search INTERPACE BIOSCIENCES, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.